CervoMed Inc. Net Change in Cash
CervoMed Inc. (CRVO) reported Net Change in Cash of $14.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-07
- CervoMed Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$293.72K, a 119.55% decline year-over-year.
- CervoMed Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $1.50M.
- CervoMed Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$1.42M.
- CervoMed Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$1.48M.
- CervoMed Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$764.03K, a 163.32% decline from fiscal 2024.
- CervoMed Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $1.21M, a 67.38% decline from fiscal 2023.
- CervoMed Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $3.70M.
- CervoMed Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$2.57M, a 113.69% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.23M 10-Q · filed 2026-08-07 | |||||||
| 2026-03-31 | -$293.72K 10-Q · filed 2026-05-15 | |||||||
| 2025-12-31 | -$764.03K 10-K · filed 2026-03-13 | |||||||
| 2025-09-30 | $437.90K 10-Q · filed 2025-11-07 | |||||||
| 2025-06-30 | -$678.78K 10-Q · filed 2026-08-07 | |||||||
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-15 | |||||||
| 2024-12-31 | $1.21M 10-K · filed 2026-03-13 | |||||||
| 2024-09-30 | -$49.18K 10-Q · filed 2025-11-07 | |||||||
| 2024-06-30 | $2.22M 10-Q · filed 2025-08-08 | |||||||
| 2024-03-31 | -$1.42M 10-Q · filed 2025-05-12 | |||||||
| 2023-12-31 | $3.70M 10-K · filed 2025-03-17 | |||||||
| 2023-09-30 | $6.33M 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | -$3.44M 10-Q · filed 2024-08-09 | $4.89M 10-Q · filed 2023-08-08 | ||||||
| 2023-03-31 | -$1.48M 10-Q · filed 2024-05-14 | $4.53M 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | -$2.57M 10-K · filed 2024-03-29 | -$27.20M 10-K · filed 2023-03-24 | ||||||
| 2022-09-30 | -$1.88M 10-Q · filed 2023-11-13 | -$30.73M 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | -$31.35M 10-Q · filed 2023-08-08 | |||||||
| 2022-03-31 | -$27.44M 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | $18.80M 10-K · filed 2023-03-24 | |||||||
| 2021-09-30 | $21.82M 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | $24.79M 10-Q · filed 2022-08-12 | |||||||
| 2021-03-31 | $28.12M 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | $4.34M 10-K · filed 2022-03-18 | $4.34M 10-K · filed 2021-03-17 | ||||||
| 2020-09-30 | $7.73M 10-Q · filed 2021-11-10 | |||||||
| 2020-06-30 | $11.38M 10-Q · filed 2021-08-11 | |||||||
| 2020-03-31 | -$3.35M 10-Q · filed 2021-05-07 | |||||||
| 2019-12-31 | $6.19M 10-K · filed 2021-03-17 | |||||||
| 2019-09-30 | -$1.85M 10-Q · filed 2020-11-12 | |||||||
| 2019-06-30 | $381.57K 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |